Information  X 
Enter a valid email address

GSK PLC Ord 31 1/4P (GSK)

Related News

28-Jul-2022 08:02 PM

GSK's Viiv in deal to allow generic of HIV prevention drug

A deal has been reached to allow for distribution of a low-cost generic version of a long-term preventative treatment against HIV in low-income countries where most of the world's infections occur, Unitaid and the Medicines Patent Pool announced T
28-Jul-2022 12:03 PM

IN BRIEF: GSK to supply 85 million doses of Adjupanrix vaccine to EU

GSK PLC - London-based pharmaceutical firm - Signs a framework contract with the European Commission's Health Emergency Preparedness & Response Authority. Says contract is for the reservation of future production and supply of 85 million doses
18-Jul-2022 08:32 AM

TOP NEWS: GSK completes demerger of healthcare product business

GSK PLC on Monday confirmed it has completed the demerger of consumer healthcare business as Haleon PLC. Further, GSK will implement a share consolidation. The west London-based pharmaceutical firm said shares of Haleon will be admitt
06-Jul-2022 07:20 PM

IN BRIEF: GSK shareholders vote in favour of Haleon demerger

GSK PLC - London-based pharmaceutical company - At general meeting, shareholders vote near unanimously in favour of proposed demerger of Haleon PLC from GSK, with the former's shares expected to list on the London Main Market at the open on July 1
01-Jul-2022 03:37 PM

IN BRIEF: GSK completes acquisition of Sierra Oncology

GSK PLC - London-based pharmaceutical company - Completes acquisition of Sierra Oncology Inc, for $55 per share in cash, representing a total value of $1.9 billion. Notes acquisition includes momelotinib, a late-stage potential treatment for my
28-Jun-2022 08:41 AM

GSK seeks expanded approval for shingles vaccine in Japan

GSK PLC on Tuesday announced it has submitted a regulatory application for Shingrix, a shingles vaccine, to the Japanese Ministry Health, Labour & Welfare. The new submission for adults aged 18 and older aims to expand the number of people
27-Jun-2022 06:27 AM

GSK posts positive interim results from hepatitis treatment trial

GSK PLC on Saturday announced positive interim results from its B-Clear phase IIb trial, which tested bepirovirsen as a treatment of chronic hepatitis B. Interim analysis from the trial showed that bepirovirsen had reduced levels of the hepatit
24-Jun-2022 06:51 AM

GSK and Sanofi tout positive vaccine results against Omicron

-?GSK PLC and Sanofi SA on Friday reported positive results against the Omicron variant of Covid-19 from their vaccine in a placebo-controlled trial. The trial evaluated an adjuvanted bivalent D614 and Beta vaccine candidate. It demonstrated a
23-Jun-2022 12:21 PM

TOP NEWS: GSK invests £1 billion to combat infectious diseases

GSK PLC on Thursday said it is investing £1 billion in research & development to fight infectious diseases like HIV and malaria in lower income countries over the next 10 years. The focus will be on malaria, tuberculosis, HIV and a &l
13-Jun-2022 08:52 AM

TOP NEWS: Sanofi, GSK booster jab impresses against Omicron

Sanofi SA on Monday said its Covid-19 booster jab developed alongside GSK PLC delivers a stronger immune response to the Omicron variant than other jabs. The jab produced a significant boost in antibody titers above baseline against multiple v
10-Jun-2022 08:14 AM

TOP NEWS: GSK closer to first respiratory syncytial virus vaccine

Drugmaker GSK PLC on Friday said its vaccine candidate for respiratory syncytial virus, or RSV, showed positive phase three data in older adults. The study, involving 25,000 participants from 17 countries, showed its candidate AReSVi 006 had a
06-Jun-2022 10:05 AM

GSK wins FDA approval for measles, mumps and rubella vaccine Priorix

GSK PLC on Monday said the US Food & Drug Administration has approved its Priorix vaccine for active immunisation for the prevention of measles, mumps and rubella in individuals of 12 months of age and older. The London-based pharmaceutica
01-Jun-2022 11:58 AM

UPDATE: Pfizer to exit 32% stake in GSK consumer JV Haleon after float

GSK PLC on Wednesday said it has submitted to the UK Financial Conduct Authority its plan for the demerger of its consumer healthcare arm and its listing in London and New York as Haleon. The separation will take the form of a demerger of at l
01-Jun-2022 09:05 AM

TOP NEWS: GSK files plan for consumer arm demerger with UK regulator

GSK PLC on Wednesday said it has submitted to the UK Financial Conduct Authority its plan for the demerger of its consumer healthcare arm and its listing in London and New York as Haleon. The separation will take the form of a demerger of at l
31-May-2022 10:45 AM

IN BRIEF: GSK JV ViiV gets marketing approval for Vocabria in Japan

GSK PLC - London-based pharmaceutical firm formerly known as GlaxoSmithKline - Notes ViiV Healthcare Ltd received marketing approval by Japan's Ministry of Health, Labour, & and Welfare for Vocabria used in combination with Rekambys and Eduran
31-May-2022 09:22 AM

TOP NEWS: GSK gives vaccine business shot in the arm with US purchase

GSK PLC on Tuesday said it has agreed to buy Affinivax Inc for up to $3.3 billion, to gain access its ‘highly innovative’ next-generation 24-valent pneumococcal vaccine candidate. Affinivax is a Boston, Massachusetts-based clin
30-May-2022 01:12 PM

IN BRIEF: GSK taps further talent for Haleon board

GSK PLC - west London-based pharmaceutical firm formerly known as GlaxoSmithKline - Makes further appointments to the designate board of Haleon, the independent company to be formed following the demerger of its Consumer Healthcare business. GSK's
27-May-2022 08:59 AM

GSK's HPV vaccine Cervarix approved in China for girls aged 9 to 14

GSK PLC on Friday said China's National Medical Products Administration has approved the use of its HPV vaccine Cervarix for girls aged 9 to 14. The pharmaceutical firm said that the two-dose vaccine prevents certain types of cancer-causin
16-May-2022 02:25 PM

TOP NEWS: GlaxoSmithKline changes name to GSK as demerger continues

GlaxoSmithKline PLC on Monday afternoon confirmed that it has changed its name to GSK PLC. The west London-based pharmaceutical firm first announced its intent to change its name in late April, alongside its results for the first quarter of 202
27-Apr-2022 10:06 AM

TOP NEWS: Glaxo posts quarterly profit rise; on track demerging Haleon

GlaxoSmithKline PLC on Wednesday reported a higher quarterly profit as it announced it is on track to demerge and list its consumer healthcare arm Haleon. Under demerging plans, the company aims for GSK consumer healthcare to become Haleon in J
20-Apr-2022 02:20 PM

Drugmaker GlaxoSmithKline faces strike over ‘derisory’ pay offer

Hundreds of UK workers at pharmaceutical giant GlaxoSmithKline PLC are set to strike over a ‘derisory’ pay offer way below the level of British inflation, a union said Wednesday. Unite general secretary Sharon Graham accused GSK of
19-Apr-2022 08:36 AM

GlaxoSmithKline says FDA accepts application for kidney disease drug

GlaxoSmithKline PLC on Tuesday said the US Food & Drug Administration has accepted the company's application for the review of kidney disease drug daprodustat. The Brentford, England-based pharmaceutical company described the FDA revi
13-Apr-2022 09:34 AM

TOP NEWS: GlaxoSmithKline to buy Sierra Oncology for $1.9 billion

GlaxoSmithKline PLC on Wednesday said it reached an agreement to acquire late-stage biopharmaceutical company Sierra Oncology Inc for $1.9 billion, or £1.5 billion. The Brentford, England-based pharmaceutical firm has agreed to pay 
30-Mar-2022 01:15 PM

GSK, CureVac begin development of second generation Covid-19 vaccine

GlaxoSmithKline PLC said on Wednesday it started the clinical development of its second-generation Covid-19 vaccine candidate, CV2CoV, along with German biopharmaceutical company CureVac NV. The Brentford, England-based pharmaceutical company
25-Mar-2022 08:56 PM

REPEAT: US FDA revises use for GSK's Covid-19 neutralizing antibody

GlaxoSmithKline PLC said on Friday that the US Food & Drug Administration has amended the emergency use authorization fact sheet for sotrovimab, an investigational Covid-19 neutralizing monoclonal antibody. The Brentford, England-based phar

a d v e r t i s e m e n t